SAN DIEGO & BEDFORD, Mass.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ocular Therapeutix, Inc. (NasdaqGM: OCUL) violated federal securities laws by issuing materially false and misleading statements regarding the company's business and operations. Ocular, a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States.
View this press release on the firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/ocular-therapeutix-inc-september-2017
Ocular Fails to Report Extent of Manufacturing Issues at Its Plant
On May 5, 2017, Ocular revealed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant. On July 6, 2017, Seeking Alpha reported that Ocular officials had been misleading investors about manufacturing issues and that the company failed to establish scientifically sound and appropriate test procedures for its drug products. The article further asserted that Ocular's approach to patient safety is "highly questionable" and that over half of lots manufactured by Ocular contain bad product. On this news, Ocular's stock fell over 30% to close at $7.12 per share on July 7, 2017, and has since fallen even further, closing at $6.38 per share on September 22, 2017.
Ocular Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.